Pear Therapeutics, Inc.

PEARDelisted May 2, 2023

Industry: Services-Health Services
SEC CIK: 0001835567

SEC filings (opens in a new tab)

Pear Therapeutics, Inc. was delisted on May 2, 2023; its insiders filed their last Form 4 on Apr 12, 2023; 53 institutions reported holding it in 13F filings for Q1 2023, worth $20.7M in total; no superinvestor held it.

Key figures

Market cap: –; Not available
Insider buys: 0; Open market, last 90 days
Insider sells: 0; Open market, last 90 days
13F holders: 53; Q1 2023, −9 vs. previous quarter
13F value: $20.7M; Reported value at the end of Q1 2023
Superinvestors holding: 0; At the end of Q1 2023

Financials

See financial statements

From SEC filings, in USD.

Revenue, FY2022: $12.7M; +201.7% year over year
Net income, FY2022: -$75.5M; No comparable prior period
Free cash flow, FY2022: -$117.4M; No comparable prior period
Revenue, Q4 FY2022: $2.56M; No comparable prior period

Revenue flow, FY2022

Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.

Net loss for FY2022: $75.5M (594.7% of revenue).

Superinvestors holding PEAR, Q1 2023

Go to the superinvestors tab

No superinvestor reported holding PEAR at the end of Q1 2023.

Latest insider trades

See all insider trades

Open-market purchases and sales by Pear Therapeutics, Inc. insiders from Form 4, newest first.

Insider trades
Filed (ET)	Trade date	Filing delay	Insider	Transaction	Shares	Avg price	Value	Holding change	Flags
Apr 12, 2023 (view filing)4:51 PM ET	Apr 10	2 days	Rocklage Scott M and 7 others10% Owner	SSaleClass A Common Stock	−16.5M	$0.12	−$1.99M	−98.8%200.0K after	3 lots
Jan 24, 2023 (view filing)	Jan 20	4 days	O'Brien RonanGC, CCO & Secretary	SSaleClass A Common Stock	−12.2K	$1.13	−$13.7K	−39.5%18.6K after
Jan 24, 2023 (view filing)	Jan 20	4 days	Strandberg JuliaChief Commercial Officer	SSaleClass A Common Stock	−12.7K	$1.13	−$14.3K	−30.7%28.6K after
Jan 24, 2023 (view filing)	Jan 20	4 days	Brenner Erin K.Chief Product Dev. Officer	SSaleClass A Common Stock	−8.69K	$1.13	−$9.82K	−16.7%43.3K after
Jan 24, 2023 (view filing)	Jan 20	4 days	Snow EllenChief Accounting Officer	SSaleClass A Common Stock	−8.03K	$1.13	−$9.07K	−25.6%23.3K after
Jan 24, 2023 (view filing)	Jan 20	4 days	Guiffre Christopherd TCFO, COO, Treas., & Asst. Sec.	SSaleClass A Common Stock	−19.5K	$1.13	−$22.1K	−39.5%30.0K after
Jan 24, 2023 (view filing)	Jan 20	4 days	Maricich YuriChief Medical Officer	SSaleClass A Common Stock	−12.2K	$1.13	−$13.7K	−11.4%94.3K after
Jan 24, 2023 (view filing)	Jan 20	4 days	McCann CoreyPresident and CEO	SSaleClass A Common Stock	−34.7K	$1.13	−$39.2K	−0.4%8.21M after
Jan 24, 2023 (view filing)	Jan 20	4 days	Jeffery KatherineChief People Officer	SSaleClass A Common Stock	−7.10K	$1.13	−$8.02K	−46.1%8.30K after
Nov 15, 2022 (view filing)8:32 PM ET	Nov 11-15	4 days	Rocklage Scott M and 7 others10% Owner	SSaleClass A Common Stock	−105.3K	$2.74	−$288.3K	−16.4%534.9K after	6 lots

Top 10 13F holders, Q1 2023

See all 53 holders

The largest institutional positions in Pear Therapeutics, Inc. at the end of Q1 2023; share changes are against Q4 2022.

Institutions holding PEAR in Q1 2023
Institution	Shares	Value	% of portfolio	Change in shares	Action
Temasek Holdings (Private) Ltd	26,803,573	$6.83M	0.04%	00.0%	Unchanged
5AM Venture Management, LLC	16,744,113	$4.27M	1.09%	00.0%	Unchanged
Softbank Group Corp	12,100,078	$3.09M	0.04%	+12,100,078	New
Arboretum Ventures, LLC	10,859,050	$2.77M	8.16%	+10,859,050	New
BlackRock Inc.	3,358,886	$856.5K	0.00%	−98,253−2.8%	Reduced
Vanguard Group Inc	2,483,472	$633.3K	0.00%	+712,450+40.2%	Added
TB Alternative Assets Ltd.	2,071,865	$528.3K	0.13%	00.0%	Unchanged
Geode Capital Management, LLC	1,050,879	$268.0K	0.00%	+1,934+0.2%	Added
State Street Corp	1,007,380	$256.9K	0.00%	−22,498−2.2%	Reduced
Perceptive Advisors LLC	900,548	$229.6K	0.01%	00.0%	Unchanged